Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Oliver Siedentopf"'
Publikováno v:
Poster Presentations.
Autor:
Franziska Fimm-Todt, Ezgi Dikici, Katharina Schaich, Oliver Siedentopf, Joachim Lauterwasser, Daniel Feger, Jan Erik Ehlert
Publikováno v:
Cancer Research. 83:549-549
The proto-oncogene KRas is a well-described small GTPase that functions as a molecular switch for major physiological signaling pathways involved in cell proliferation, differentiation and survival. It has been shown that activating mutations in KRas
Autor:
Carla Castro, Philipp Metzger, Daniel Feger, Sarah Ulrich, Oliver Siedentopf, Jan E. Ehlert, Holger Weber
Publikováno v:
Cancer Research. 83:4419-4419
With the development and approval of cutting-edge immune-based approaches for cancer treatment in recent years, the global immune-oncological (IO) pipelines have dramatically increased. To overcome the challenges of rising treatment resistance, new s
Publikováno v:
Cancer Research. 82:2893-2893
Bispecific antibodies are being explored as a means to modulate responses of the immune system to tumor infiltration. They are emerging as a growing class of immunotherapies with potential to further improve clinical efficacy and safety. Besides tumo
Autor:
Vincent Vuaroqueaux, Daniel Feger, Anne-Lise Peille, Oliver Siedentopf, Sadhana Panzade, Sarah Ulrich, Sebastian Dempe, Heinz-Herbert Fiebig, Jan Erik Ehlert
Publikováno v:
Cancer Research. 82:1132-1132
Adavosertib (AZD1775, MK-1775), a clinical stage inhibitor of the tyrosine kinase WEE1, was investigated in a cell proliferation and survival assay with 140 human cancer cell lines (CLs) representing all major tumor types (ProLiFiler platform of Reac
Publikováno v:
Cancer Research. 82:357-357
The KRas/Raf/MEK signalling axis has been identified to play a critical role in the formation of cancer, resulting in several investigational new drugs targeting this pathway. Identification of appropriate drugs is hampered, however, by the assumptio
Autor:
Franziska Fimm-Todt, Joachim Lauterwasser, Eva-Maria Egenter, Christian Weber, Daniel Feger, Katharina Schaich, Sarah Ulrich, Oliver Siedentopf, Frank Totzke, Michael Kubbutat, Jan Erik Ehlert
Publikováno v:
Cancer Research. 82:4072-4072
Leucin-rich repeat kinase 2 (LRRK2) plays an important role in the onset of sporadic as well as familial Parkinson’s disease. Pathogenic gain-of-function mutations of LRRK2 are associated with aberrant LRRK2 hyperactivity which results in neurotoxi
Autor:
Vincent Vuaroqueaux, Oliver Siedentopf, Sarah Ulrich, Anne-Lise Peille, Sebastian Dempe, Daniel Feger, Hoor Al-Hasani, Heinz-Herbert Fiebig, Jan E. Ehlert
Publikováno v:
Cancer Research. 81:1027-1027
Testing novel anti-cancer agents across large panel of tumor models covering genetic diversity of cancers is increasingly considered as a cornerstone of preclinical development. For this purpose, Reaction Biology developed “ProLiFiler” a standard
Autor:
Marianne Birkle, Ralph Graeser, Sarah Umber, Christoph Schaechtele, Frank Totzke, Daniel Müller, Kurt Ballmer-Hofer, Daniel Feger, Oliver Siedentopf, Alexandra Ortiz, Holger Weber, Constance Ketterer, Michael H.G. Kubbutat, Jan E. Ehlert, Melanie Müller
Publikováno v:
Journal of biomolecular screening
Many receptor tyrosine kinases (RTKs) represent bona fide drug targets in oncology. Effective compounds are available, but treatment invariably leads to resistance, often due to RTK mutations. The discovery of second-generation inhibitors requires ce
Autor:
Sarah Umber, Marianne Birkle, Alokta Chakrabarti, Daniel Feger, Orysya Stus, Oliver Siedentopf, Frank Totzke, Thomas Weber, Jan E. Ehlert, Michael H.G. Kubbutat, Marcel Pathe
Publikováno v:
Molecular Cancer Therapeutics. 17:B159-B159
TAM kinases, a relatively recent group of RTKs, have gained interest as therapeutic targets in cancer, chronic inflammatory, and autoimmune diseases. Comprising Tyro-3, Axl, and MerTK, TAMs need an extracellular lipid-protein complex for their activa